Design by Userking
April 23, 2014
View Cart

23 Skidoo: FDA’s Genomics Clampdown Gets Mixed Reviews

By Erik Goldman - Vol. 15, No. 1. Spring, 2014

The FDA’s recent regulatory action against popular genomic testing company, 23andMe, is generating mixed responses among integrative clinicians.

skidoo-main-imageLate in November, the FDA issued a widely publicized warning letter calling 23andMe’s test an unapproved diagnostic device, and ordering the company to discontinue its Personal Genome Service (PGS), an injunction 23andMe quickly obeyed. FDA holds that available data are insufficient to support the company’s gene-based health risk assessments.

23andMe will continue offering basic DNA data, but can no longer provide it’s popular health risk interpretations—explanations in lay terms focused on 254 common disorders, carrier status for known genetic diseases, and likely responses to common drugs.

[ ...Read More ]

Featured Articles

Clearing the Air? The Benefits & Risks Of Electronic Cigarettes

Written by Kristen Schepker

In recent years, there has been an explosion in the popularity of electronic cigarettes. Marketed as a trendy alternative to traditional tobacco products, electronic cigarettes--known as e-cigs--are often touted as a safer, healthier habit.

[ ...Read More ]

Lymphatic Enhancement Technology: Treating the “Other Circulatory System”

Written by Erik Goldman

let-therapy-2When physicians use the phrase "lymph node," it's more often than not followed by the word "excision" or "biopsy."

[ ...Read More ]

Copyright @ 2014 Holistic Primary Care. All Rights Reserved.